AlzeCure Pharma (ALZCUR) Status Update summary

Orphan drug market overview

• Orphan drugs target rare diseases, defined as affecting fewer than 200,000 people in the U.S. or fewer than 5 in 10,000 in the EU, with ultra-orphan diseases affecting even smaller populations.

• The global orphan drug market reached $195.2 billion in 2024, growing at 10–12% annually, double the rate of the broader pharma sector.

• Orphan drugs benefit from incentives like faster development, long market exclusivity (7 years U.S., 10 years EU), and regulatory support.

• Premium pricing and high unmet medical need drive strong commercial interest from both big pharma and investors.

• Orphan drug development has pioneered precision medicine, with targeted therapies and advanced diagnostics now influencing broader healthcare.

ACD 440 and erythromelalgia opportunity

• ACD 440 is a topical TRPV1 antagonist gel developed for pain in erythromelalgia, a rare, chronic, and severe pain disorder with no effective treatments.

• Erythromelalgia affects an estimated 43,000–70,000 individuals in the U.S., qualifying for orphan status, and is characterized by intense, heat-triggered pain flares.

• Current management relies on cooling, which can cause complications; there are no approved or effective drugs for this indication.

• ACD 440 has shown a 50% reduction in heat-induced pain in both healthy subjects and patients with chronic neuropathic pain in clinical studies.

• Orphan drug designation for ACD 440 in erythromelalgia brings regulatory, financial, and market exclusivity advantages, with positive FDA feedback on the development program.

Development and commercialization strategy

• The next steps include optimizing the development program for erythromelalgia, working with CROs, and addressing FDA feedback.

• The business development strategy is to out-license ACD 440 to partners with established relationships in specialty care (pain specialists, dermatologists, neurologists, rheumatologists, pediatricians).

• The erythromelalgia market is valued at approximately $2.6 billion, with no other active development projects identified.

• Additional orphan indications, such as subgroups of diabetic polyneuropathy with burning pain, are being explored for ACD 440.

• The company is pursuing global opportunities, initially focusing on the U.S., but also targeting the EU and Japan.